Page last updated: 2024-08-23

epirubicin and Hematologic Diseases

epirubicin has been researched along with Hematologic Diseases in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19907 (17.50)18.7374
1990's15 (37.50)18.2507
2000's16 (40.00)29.6817
2010's2 (5.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C1
Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS1
Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G1
Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G1
Belmans, A; Brouwers, B; Dieudonné, A; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Schöffski, P; van Brussel, T; Vulsteke, C; Wildiers, H1
Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G1
Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K1
Bonneterre, J; Catimel, G; Tubiana-Hulin, M1
Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS1
Choi, CW; Choi, IK; Choi, JG; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sul, HR; Sung, HJ; Yoon, SY1
Avilés, A; Castañeda, C; Cleto, S; Nambo, MJ; Neri, N1
Aravantinos, G; Fountzilas, G; Gogas, H; Kalofonos, HP; Klouvas, G; Kosmidis, P; Makatsoris, T; Papakostas, P; Pectasides, D; Tsavdaridis, D; Xanthakis, I1
Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N1
Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS1
Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S1
Farabegoli, G; Ganzina, F; Giovannini, M; Martoni, A; Monetti, N; Pannuti, F; Tomasi, L1
Martini, A; Moro, E; Natale, N; Pacciarini, MA; Piazza, E; Tamassia, V1
Canavese, G; Catturich, A; Del Mastro, L; Garrone, O; Guenzi, M; Rosso, R; Sertoli, MR; Venturini, M1
Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H1
Falk, M; Fridrik, MA; Haidinger, R; Hausmaninger, H; Klocker, J; Linkesch, W; Neubauer, M; Pont, J; Radaszkiewicz, T; Raudaschl, G; Schiller, L; Seewann, HL; Sill, H; Stöger, M1
Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM1
Horikawa, K; Okada, Y; Sano, M1
Ashley, S; Chang, JC; Gregory, RK; Powles, TJ1
Anker, G; Bengtsson, NO; Bennmarker, H; Bergh, J; Erikstein, B; Fornander, T; Kellokumpu-Lehtinen, P; Malmström, P; Wiklund, T; Wilking, N1
Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D1
Bianco, AR; Carlomagno, C; Casella, G; De Placido, G; De Placido, S; Ferrari, E; Fiorentino, R; Iodice, F; Lauria, R; Maffeo, A; Morabito, A; Perrone, F; Pignata, S; Ricchi, P; Tramontana, S; Varriale, E1
Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A1
Bellelli, T; Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gallo, C; Lauria, R; Limite, G; Martignetti, A; Perrone, F; Petrella, G1
Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M1
Burstein, HJ; Winer, EP1
Biesma, B; Giaccone, G; Huisman, C; Postmus, PE; Schramel, FM; Smit, EF1
Guaraldi, M; Martoni, A; Melotti, B; Pacciarini, MA; Pannuti, F; Riva, A1
Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F1
Arian-Schad, K; Hackl, A; Heydarfadai, M; Lahousen, M; Petru, E; Pickel, H; Stettner, H1
Coombes, RC; Cunningham, D; Haydock, A; Hickish, T1
Bishop, J; Brodie, G; Burns, W; Coates, A; Levi, J; Raghavan, D; Schwarz, M; Snyder, R; Tattersall, M; Thomson, D1
Bastholt, L; Bramwell, V; Buesa, J; Mouridsen, HT; Mulder, JH; Pinedo, HM; Santoro, A; Somers, R; Thomas, D; van Oosterom, AT1
Bezwoda, WR1
Casper, ES; Cassidy, C; Currie, V; Geller, NL; Hakes, TB; Jain, KK; Kaufman, RJ; Petroni, GR; Schwartz, W; Young, CW1

Reviews

3 review(s) available for epirubicin and Hematologic Diseases

ArticleYear
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Actas urologicas espanolas, 2014, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine

2014
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
    Breast cancer research : BCR, 2008, Volume: 10, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine

2008
New combinations with Herceptin in metastatic breast cancer.
    Oncology, 2001, Volume: 61 Suppl 2

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine

2001

Trials

28 trial(s) available for epirubicin and Hematologic Diseases

ArticleYear
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome

2008
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
    British journal of cancer, 2002, Aug-27, Volume: 87, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome

2002
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
    Oncology, 2004, Volume: 66, Issue:3

    Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left

2004
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Onkologie, 2005, Volume: 28, Issue:6-7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome

2005
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Hematologic Diseases; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Survival Analysis; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Uracil

2006
Rituximab and dose dense chemotherapy in primary breast lymphoma.
    Haematologica, 2007, Volume: 92, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Middle Aged; Nervous System Diseases; Prednisone; Rituximab; Survival Analysis; Treatment Outcome; Vincristine

2007
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome

2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen

2008
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome

2007
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Journal of the National Cancer Institute, 2008, Mar-19, Volume: 100, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Staging; Patient Compliance; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome; Vomiting

2008
Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
    International journal of clinical pharmacology research, 1984, Volume: 4, Issue:3

    Topics: Aged; Doxorubicin; Epirubicin; Female; Hematologic Diseases; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Models, Biological; Neoplasms

1984
A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Pilot Projects

1994
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Ethinyl Estradiol; Female; Fever; Fluorouracil; Hematologic Diseases; Humans; Infections; Length of Stay; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction

1993
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Feasibility Studies; Female; Folic Acid; Hematologic Diseases; Humans; Ifosfamide; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Remission Induction; Risk Factors; Survival Rate; Vincristine

1996
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Nausea; Premenopause; Regression Analysis; Survival Analysis; Vomiting

1996
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Humans; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prospective Studies; Survival Rate; Vincristine

1997
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Mastectomy, Radical; Middle Aged; Prognosis; Recombinant Proteins; Treatment Outcome

1998
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Haematologica, 1998, Volume: 83, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine

1998
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Oncology, 1999, Volume: 56, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Leukocyte Count; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recombinant Proteins; Treatment Outcome

1999
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycins; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Survival Rate

1999
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    International journal of oncology, 1999, Volume: 15, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Humans; Neoplasm Staging; Survival Rate; Treatment Outcome

1999
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms; Vomiting

2001
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    British journal of cancer, 2001, Nov-16, Volume: 85, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome

2001
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    American journal of clinical oncology, 1991, Volume: 14, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Survival Rate

1991
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Heart Failure; Hematologic Diseases; Humans; Middle Aged; Nausea; Prospective Studies; Survival Rate

1991
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Doxorubicin; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Male; Middle Aged; Random Allocation; Sarcoma; Soft Tissue Neoplasms; Time Factors

1987
Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide.
    Medical and pediatric oncology, 1986, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Nausea; Neoplasm Staging; Nervous System Diseases; Ovarian Neoplasms; Random Allocation; South Africa

1986
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Erythrocytes; Female; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Nausea; Physical Examination; Prospective Studies; Radionuclide Imaging; Random Allocation; Stroke Volume; Technetium

1985

Other Studies

9 other study(ies) available for epirubicin and Hematologic Diseases

ArticleYear
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles

2009
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Genetic Variation; Hematologic Diseases; Humans; Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Predictive Value of Tests; Retrospective Studies

2013
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:18

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine

2002
A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms

1984
[Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:5

    Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Echocardiography; Epirubicin; Female; Heart; Hematologic Diseases; Humans; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Stroke Volume

1997
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:11-12

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms

1990
Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study.
    American journal of clinical oncology, 1991, Volume: 14, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Epirubicin; Female; Hematologic Diseases; Humans; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects; Prednimustine; Survival Rate

1991
Experience with intermediate-dose (110-120 mg/m2) epirubicin.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Dose-Response Relationship, Drug; Epirubicin; Female; Hematologic Diseases; Humans; Inflammation; Male; Middle Aged; Mucous Membrane; Nausea; Thrombophlebitis

1989
Phase I study of epirubicin given on a weekly schedule.
    Cancer treatment reports, 1987, Volume: 71, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged

1987